Novo Nordisk’s blockbuster GLP-1 agonist, Wegovy (semaglutide), gained accelerated FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH), representing the first GLP-1 drug approved for this prevalent fatty liver disease. Clinical data demonstrated Wegovy’s efficacy in improving liver scarring and resolving MASH symptoms without worsening fibrosis. This approval intensifies competition with Madrigal Pharmaceuticals’ Rezdiffra, the only other MASH-specific therapy, triggering investor reevaluations of market dynamics in this emerging indication.